Literature DB >> 11843844

Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones.

J P Maciejewski1, C Rivera, H Kook, D Dunn, N S Young.   

Abstract

Because of the insensitivity of the Ham test, paroxysmal nocturnal haemoglobinuria (PNH) has been inaccurately viewed as a late clonal complication of aplastic anaemia (AA). To clarify the relationship between PNH and marrow failure, we tested for the presence of glycosylphosphatidyl-anchored protein-deficient (GPI-AP) granulocytes in large cohorts of patients with AA, myelodysplasia (MDS), and pure haemolytic PNH. A PNH clone was detected in 32% of new AA patients and 18% of MDS patients. In serial studies, this proportion did not change up to 15 years after diagnosis, suggesting that expansion of aberrant cells is an early event (i.e. prior to initial presentation). For all patients with a PNH clone, on average 14% of PNH granulocytes were found on presentation and 37% at 10 years. Patients with PNH but without cytopenia showed higher percentages of GPI-AP-deficient cells than did those with the AA/PNH syndrome. After immunosuppression, there was no change in the contribution of PNH clone to blood production, arguing against the "immune-escape" theory in PNH. Clinically, a high proportion of GPI-AP-deficient cells correlated with marrow hypercellularity. GPI-AP-deficient cells were similarly present in patients with and without karyotypic abnormalities. Our results indicate that the GPI-AP-deficient clones show quantitative and kinetic differences between classic haemolytic PNH and PNH with marrow failure, in which the evolution rate is low later in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11843844     DOI: 10.1046/j.1365-2141.2001.03191.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

1.  Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.

Authors:  Atsushi Narita; Hideki Muramatsu; Yuko Sekiya; Yusuke Okuno; Hirotoshi Sakaguchi; Nobuhiro Nishio; Nao Yoshida; Xinan Wang; Yinyan Xu; Nozomu Kawashima; Sayoko Doisaki; Asahito Hama; Yoshiyuki Takahashi; Kazuko Kudo; Hiroshi Moritake; Masao Kobayashi; Ryoji Kobayashi; Etsuro Ito; Hiromasa Yabe; Shouichi Ohga; Akira Ohara; Seiji Kojima
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

Review 2.  Clinical management of aplastic anemia.

Authors:  Amy E Dezern; Robert A Brodsky
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

3.  Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure.

Authors:  Neal S Young
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

4.  Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia.

Authors:  Manuel G Afable; Mohammed Shaik; Yuka Sugimoto; Paul Elson; Michael Clemente; Hideki Makishima; Mikkael A Sekeres; Alan Lichtin; Anjali Advani; Matt Kalaycio; Ramon V Tiu; Christine L O'Keefe; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 5.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

6.  The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy.

Authors:  Taha Bat; Omnia N Abdelhamid; Suresh K Balasubramanian; Aly Mai; Tomas Radivoyevitch; Michael Clemente; Jaroslaw P Maciejewski
Journal:  Br J Haematol       Date:  2017-08-14       Impact factor: 6.998

7.  Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.

Authors:  Phillip Scheinberg; Michael Marte; Olga Nunez; Neal S Young
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

Review 8.  Diagnosis and Treatment of Aplastic Anemia.

Authors:  Scott A Peslak; Timothy Olson; Daria V Babushok
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 9.  Management issues in paroxysmal nocturnal hemoglobinuria.

Authors:  Gabrielle Meyers; Charles J Parker
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

10.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.